Type 1 and Type 2 diabetes, general endocrinology.
MD: Brown University; Residency: University of Rochester/Strong Memorial Hospital, 1992-1995; Endocrinology and Metabolism Fellowship: University of Rochester/Strong Memorial Hospital, 1995-1998; Senior Instructor in Medicine: Division of Endocrinology/Clinical Research Center, Department of Medicine, University of Rochester, June 1998-December 1998; Endocrinologist: FirstHealth of the Carolinas, May 1999-October 2002; Assistant Professor of Medicine: University of North Carolina Division of Endocrinology, January 1999-August 2008; Associate Professor of Medicine: University of North Carolina Division of Endocrinology, September 2008-present.
Dr. Dostou teaches trainees (medical students, residents, endocrinology fellows) on a variety of levels within the UNC school of medicine. She is especially active in clinical care and enjoys seeing patients with various endocrine disorders, in particular those who have diabetes.
As part of the clinical research team of the UNC Diabetes Care Center at Meadowmont, Dr. Dostou has led trials in diabetes prevention, immunotherapy, cardiovascular assessment, and various novel treatments for type 1 and type 2 diabetes.
Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20. PMID: 2619363
Rigby, MR, DeMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Chetanbabu MP, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell W, Pinckney A, Keyes Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom G, McNamara J, Ehlers M, the TIDAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Diabetes & Endocrinology, 23 September 2013 doi:10.1016/S2213-8587(13)70111-6. Pubmed PMID: 24622414.
Tandon S, Wackers FJ, Inzucchi SE, Bansal S, Staib LH, Chyun DA, Davey JA, Young LH; DIAD Investigators. Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study. Diab Vasc Dis Res. 2012 Apr;9(2):124-30. Pubmed PMID: 23412077